Cart
sales@molnova.com
Ubrogepant
CAS No. 1374248-77-7
Ubrogepant( MK-1602 | MK1602 )
Catalog No. M11544 CAS No. 1374248-77-7
Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 437 | In Stock |
|
| 10MG | 696 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUbrogepant
-
NoteResearch use only, not for human use.
-
Brief DescriptionUbrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.
-
DescriptionUbrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.Migraine Phase 3 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsMK-1602 | MK1602
-
PathwayGPCR/G Protein
-
TargetCGRP Receptor
-
RecptorCGRP Receptor
-
Research AreaNeurological Disease
-
IndicationMigraine
Chemical Information
-
CAS Number1374248-77-7
-
Formula Weight549.554
-
Molecular FormulaC29H26F3N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (454.93 mM)
-
SMILESO=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=CC=CC=C6)C5)=O
-
Chemical Name(3'S)-1',2',5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxospiro[6H-cyclopenta[b]pyridine-6,3'-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li CC, et al. J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021.
2. Holland PR, et al. Neurotherapeutics. 2018 Apr;15(2):304-312.
3. Voss T, et al. Cephalalgia. 2016 Aug;36(9):887-98.
molnova catalog
related products
-
Calcitonin salmon
Calcitonin salmon, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.
-
Atogepant
A potent, selective and orally available CGRP receptor antagonist for the prevention of migraine.
-
Erenumab
Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attacks.
